Evidence map›Paper›PMID 25514926›Full record

ArticleNucleic acids research2015

PhosphoSitePlus, 2014: mutations, PTMs and recalibrations.

Peter V Hornbeck, Bin Zhang, Beth Murray, Jon M Kornhauser, Vaughan Latham, Elzbieta Skrzypek

Abstract read
In one paragraph

Article in Nucleic acids research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2,072 papers.

0numbers the graph read from it
0cells of the map it votes in
2,072citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2,072 citing papers in PubMed.

  1. Pathway and Kinase Analysis in Proteomics and Phosphoproteomics with rROMA.Methods in molecular biology (Clifton, N.J.) · 2027
    Article
  2. AKT Phosphorylation of FOXK2 at Ser398 Impacts Breast Cancer Cell Growth and Viability.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  3. Review
  4. WEE1 opposes APC/CNature · 2026
    Article
  5. Predicting Functional Diversity Within Enzyme Families: A Practical Perspective.Chembiochem : a European journal of chemical biology · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Positive selection screen identifies natural product β-catenin inactivators.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

2,012 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Peter V HornbeckCell Signaling Technology, 3 Trask Lane, Danvers, MA 01923, USA phornbeck@cellsignal.com.
Bin ZhangCell Signaling Technology, 3 Trask Lane, Danvers, MA 01923, USA.
Beth MurrayCell Signaling Technology, 3 Trask Lane, Danvers, MA 01923, USA.
Jon M KornhauserCell Signaling Technology, 3 Trask Lane, Danvers, MA 01923, USA.
Vaughan LathamCell Signaling Technology, 3 Trask Lane, Danvers, MA 01923, USA.
Elzbieta SkrzypekCell Signaling Technology, 3 Trask Lane, Danvers, MA 01923, USA.

Funding

Data Coordination and Integration Center for LINCS-BD2KU54HL127624 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MA'AYAN, AVI, SCHURER, STEPHAN C · 2014 to 2019
$23.5M
PhosphoSite. and the Phosphoproteome of CancerR44CA126080 · NCI · CELL SIGNALING TECHNOLOGY, INC. · PI HORNBECK, PETER VAN · 2006 to 2009
$1.3M
Development of a Protein Phosphorylation Site DatabaseR44AA014848 · NIAAA · CELL SIGNALING TECHNOLOGY, INC. · PI HORNBECK, PETER VAN · 2003 to 2004
$1.2M
Development of a Protein Phosphorylation Site DatabaseR43GM065768 · NIGMS · CELL SIGNALING TECHNOLOGY, INC. · PI HORNBECK, PETER VAN · 2002 to 2002
$156k
NCI NIH HHS R44 CA126080NCI NIH HHS R44CA126080NHLBI NIH HHS U54 HL127624NHLBI NIH HHS U54-HL127624-01NIAAA NIH HHS R44 AA014848NIAAA NIH HHS R44AA014848MNIGMS NIH HHS R43GM065768
6 · The paper itself

Abstract

PhosphoSitePlus(®) (PSP, http://www.phosphosite.org/), a knowledgebase dedicated to mammalian post-translational modifications (PTMs), contains over 330,000 non-redundant PTMs, including phospho, acetyl, ubiquityl and methyl groups. Over 95% of the sites are from mass spectrometry (MS) experiments. In order to improve data reliability, early MS data have been reanalyzed, applying a common standard of analysis across over 1,000,000 spectra. Site assignments with P > 0.05 were filtered out. Two new downloads are available from PSP. The 'Regulatory sites' dataset includes curated information about modification sites that regulate downstream cellular processes, molecular functions and protein-protein interactions. The 'PTMVar' dataset, an intersect of missense mutations and PTMs from PSP, identifies over 25,000 PTMVars (PTMs Impacted by Variants) that can rewire signaling pathways. The PTMVar data include missense mutations from UniPROTKB, TCGA and other sources that cause over 2000 diseases or syndromes (MIM) and polymorphisms, or are associated with hundreds of cancers. PTMVars include 18 548 phosphorlyation sites, 3412 ubiquitylation sites, 2316 acetylation sites, 685 methylation sites and 245 succinylation sites.

Indexed as

Databases, ProteinProtein Processing, Post-TranslationalDiseaseInternetMutationMutation, MissensePhosphorylationPosition-Specific Scoring MatricesProtein KinasesProtein Structure, TertiarySequence Analysis, ProteinSignal TransductionProtein Kinases

Identifiers

PMID25514926
PMCPMC4383998

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.